Objectives
To compare the risk of non‐skin cancer in LRRK2 mutation carriers and individuals with idiopathic Parkinson's disease (iPD), explore the age at which LRRK2 mutation carriers have cancer ...compared to iPD subjects, and clarify whether certain cancers are more closely associated with the LRRK2 mutation than iPD.
Materials and Methods
Demographic data and cancer outcomes from 830 iPD patients and 103 LRRK2 mutation carriers (27 with PD) were retrospectively collected. Oncologic data were obtained from the Cancer Registry of Norway and included cancer type and age at cancer. All study participants were of Norwegian ethnicity.
Results
LRRK2 mutation carriers have increased risk of non‐skin cancer compared with iPD subjects (OR 2.09; 95% CI 1.16–3.77; p = .015). A significant association was found between the mutation and breast cancer in women (OR 4.58; 95% CI 1.45–14.51; p = .010). No other associations between harboring a LRRK2 mutation and specific cancer types were uncovered.
Conclusion
LRRK2 mutation carriers have an increased risk of non‐skin cancer compared with iPD subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women. The increased risk is likely independent of ethnicity.
Patients with Parkinson's disease (PD) have a reduced risk of cancer. However, gene mutations resulting in PD have also been implicated in cancer. Mutations in the LRRK2 gene are the most common genetic cause of PD. LRRK2 mutation carriers have an increased risk of non‐skin cancer compared with iPD subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women.
Abstract
Objectives
To compare the risk of non‐skin cancer in
LRRK
2
mutation carriers and individuals with idiopathic Parkinson's disease (
iPD
), explore the age at which
LRRK
2
mutation carriers ...have cancer compared to
iPD
subjects, and clarify whether certain cancers are more closely associated with the
LRRK
2
mutation than
iPD
.
Materials and Methods
Demographic data and cancer outcomes from 830
iPD
patients and 103
LRRK
2
mutation carriers (27 with
PD
) were retrospectively collected. Oncologic data were obtained from the Cancer Registry of Norway and included cancer type and age at cancer. All study participants were of Norwegian ethnicity.
Results
LRRK
2
mutation carriers have increased risk of non‐skin cancer compared with
iPD
subjects (
OR
2.09; 95%
CI
1.16–3.77;
p
=
.015). A significant association was found between the mutation and breast cancer in women (
OR
4.58; 95%
CI
1.45–14.51;
p
=
.010). No other associations between harboring a
LRRK
2
mutation and specific cancer types were uncovered.
Conclusion
LRRK
2
mutation carriers have an increased risk of non‐skin cancer compared with
iPD
subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women. The increased risk is likely independent of ethnicity.
PDF
